Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06131398 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study of AMG 355 Alone and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors

Name: A Study of AMG 355 Alone and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors — clinical trial record (NCT06131398)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusCompleted

PhasePhase 1

SponsorAmgen

Started2024-03-07

View on ClinicalTrials.gov ↗

The primary objectives of this study are to: * Evaluate the safety and tolerability of AMG 355 as monotherapy and in combination with pembrolizumab in participants with advanced solid tumors * Determine the recommended phase 2 dose and the maximum tolerated dose for AMG 355 as monotherapy and in combination with pembrolizumab in participants with advanced solid tumors.

Amendment history 1 change detected by DataLookout

2026-08-12

Trial completed

Trial Details

NCT Number	NCT06131398
Lead Sponsor	Amgen
Conditions	Advanced Solid Tumors
Enrollment	77 participants
Start Date	2024-03-07
Primary Completion	2026-07-22 (estimated)
Study Completion	2026-07-22 (estimated)
Updated on ClinicalTrials.gov	2026-08-11